The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy
Metrics: PDF 613 views | HTML 672 views | ?
Hongfei Ji1,3,*, Qijia Xuan2,*, Caichuan Yan1,3, Tao Liu2, Abiyasi Nanding4, Qingyuan Zhang1,2,3
1Department of Cancer Molecular and Biology, Cancer Institute, Harbin Medical University, Harbin, China
2Department of Medical Oncology, Tumor Hospital of Harbin Medical University, Harbin, China
3Department of Cancer Molecular and Biology, Heilongjiang Academy of Medical Sciences, Harbin, China
4Department of Pathology, Tumor Hospital of Harbin Medical University, Harbin, China
*These authors have contributed equally to this work
Qingyuan Zhang, e-mail: email@example.com
Keywords: breast cancer, lymphocyte-to-monocyte ratio, 5-fluorouracil, prognostic factor
Received: December 03, 2015 Accepted: April 11, 2016 Published: April 26, 2016
Several reports have suggested that peripheral blood-based parameters are associated with host immunity response, which is an essential component of the pathogenesis and progression of cancer. The purpose of the present study was to identify the prognostic significance of various peripheral blood-based biomarkers and to determine the optimal cut-off value suitable for luminal breast cancer patients. We found that lymphocyte-to-monocyte ratio (LMR) was significant prognostic predictors. And the patients with a CEF regimen and LMR ratio ≥ 5.2 gained a good prognosis. This study suggested that the LMR could be regarded as an independent prognostic factor in luminal breast cancer patients. The elevated LMR level also had enhanced 5-fluorouracil sensitivity in luminal breast cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.